Diagnostic performance of somatostatin receptor PET/CT using 68Ga-DOTANOC in gastrinoma patients with negative or equivocal CT findings

Naswa, Niraj; Sharma, Punit; Soundararajan, Ramya; Karunanithi, Sellam; Nazar, Aftab Hasan; Kumar, Rakesh; Malhotra, Arun; Bal, Chandrasekhar

doi:10.1007/s00261-012-9925-z

Cited by 35 publications

(29 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results might be explained by the previously mentioned difficult interpretations of uptake in the normal pancreatic tissue. In 25 patients with clinically defined gastrinomas with equivocal or negative findings on CT, Naswa et al reported a sensitivity of 68% using 68 Ga-DOTANOC [65].…”

Section: Studymentioning

confidence: 97%

Pet Tracers for Somatostatin Receptor Imaging of Neuroendocrine Tumors: Current Status and Review of the Literature

2014

View full text Add to dashboard Cite

Neuroendocrine tumors have shown rising incidence mainly due to higher clinical awareness and better diagnostic tools over the last 30 years. Functional imaging of neuroendocrine tumors with PET tracers is an evolving field that is continuously refining the affinity of new tracers in the search for the perfect neuroendocrine tumor imaging tracer. (68)Ga-labeled tracers coupled to synthetic somatostatin analogs with differences in affinity for the five somatostatin receptor subtypes are now widely applied in Europe. Comparison of sensitivity between the most used tracers - (68)Ga-DOTA-Tyr3-octreotide, (68)Ga-DOTA-Tyr3-octreotate and (68)Ga-DOTA-l-Nal3-octreotide - shows little difference and expertise on the specific tracer used, and knowledge regarding physiological uptake might be more important than in vitro-proven differences in affinity. Using isotopes such as (18)F or (64)Cu might improve these PET tracers further.

show abstract

Section: Studymentioning

confidence: 97%

Pet Tracers for Somatostatin Receptor Imaging of Neuroendocrine Tumors: Current Status and Review of the Literature

2014

View full text Add to dashboard Cite

show abstract

“…Using tumor imaging studies in combination with the hypergastrinemia to diagnose ZES, as is increasingly being done in recently reported cases [82, 84, 87, 88, 90, 94, 110, 134] with patients taking or not taking PPIs, has other limitations. In the presence of PPI therapy, one cannot exclude the presence of appropriate hypergastrinemia if a tumor is seen on cross-sectional imaging studies (CT, ultrasound, or MRI), whether the patient has MEN1 syndrome or not and the mass itself may not even be a NET.…”

Section: Proposed Solutions To the Current Controversies In The mentioning

confidence: 99%

Diagnosis of Zollinger–Ellison Syndrome in the Era of Ppis, Faulty Gastrin Assays, Sensitive Imaging and Limited Access to Acid Secretory Testing

Metz

Cadiot

Poitras

et al. 2017

Int. J. Endo. Oncol.

View full text Add to dashboard Cite

In recent years the diagnosis of Zollinger-Ellison syndrome (ZES) has become increasingly controversial with several new approaches and criteria proposed, differing from the classical biochemical criterion of inappropriate hypergastrinemia (i.e., hypergastrinemia in the presence of hyperchlorhydria) (Table 1). These changes have come about because of the difficulty and potential dangers of stopping proton pump inhibitors (PPIs) for gastric acid analysis; the recognition than many of the current assays used to assess gastrin concentrations are unreliable; the development of sensitive imaging modalities that detect neuroendocrine tumors (NETs) including an increasing number of the primary gastrinomas; the increased use of percutaneous or endoscopic ultrasound (EUS)-directed biopsies/cytology and the general lack of availability of acid secretory testing. In this article we will discuss the basis for these controversies, review the proposed changes in diagnostic approaches and make recommendations for supporting the diagnosis of ZES in the modern era.

show abstract

“…A high prevalence of somatostatin receptor expression among NETs provides the rationale for peptide receptor-targeted therapy as a treatment modality in patients with inoperable or metastatic disease. The most frequently used radionuclides for targeted radiotherapy in NETs are indium ( 111 In), yttrium ( 90 Y), and lutetium ( 177 Lu), which differs in emitted particles, energy and tissue penetration [52][53]. Both the yttrium-and the lutetium-labeled compounds have demonstrated promising results in patients with NET [54][55].…”

Section: Therapymentioning

confidence: 99%

“…Diagnostic performance of 68 Ga-DOTANOC PET/CT was superior in patients with equivocal ceCT findings than that in patients with negative ceCT. 68 Ga-DOTANOC PET/CT showed more accuracy than ceCT [52].…”

Section: Stagingmentioning

confidence: 99%

68Ga-Somatostatin Analogue PET/CT in Neuroendocrine Tumors

Giovannini¹,

Gaeta²,

Ciarmiello³

2014

J Diagn Imaging Ther

View full text Add to dashboard Cite

Neuroendocrine tumors (NETs) include a spectrum of neoplasms characterized by histologic heterogeneity with significant clinical differences. Generally are well differentiated tumors but often present metastases at diagnosis. Conventional imaging techniques result insufficient in early diagnosis and therapy monitoring. Standardized morphological criteria to assess treatment response are inadequate in NETs, because of their biologic evolution and the cytostatic nature of new oncologic treatments. Functional imaging modalities have improved the understanding and diagnosis of NETs by the use of somatostatin analogue tracers labelled with radioisotopes.111 In-Octreotide scintigraphy was considered the gold standard imaging modalities for NET detection with a diagnostic accuracy approximately of 90%. Actually 68 Ga-Dota-SST radiotracers (SSTRTs) PET/CT represent a superior imaging procedure with higher accuracy in detection of NET lesions as compared to morphological imaging procedures and somatostatin receptor scintigraphy. Additionally, the use of somatostatin analogue radiolabelled tracers offers the possibility to non-invasively evaluate the presence of somatostatin receptor expression on NET cells, with direct therapeutic implications. However, in the management of patients with NETs and in the evaluation of response to therapy the specialists

show abstract

Diagnostic performance of somatostatin receptor PET/CT using 68Ga-DOTANOC in gastrinoma patients with negative or equivocal CT findings

Abstract: (68)Ga-DOTANOC PET/CT appears to be useful in patients with gastrinoma with negative or equivocal results on CECT, especially the latter group.

Cited by 35 publications

References 27 publications

Pet Tracers for Somatostatin Receptor Imaging of Neuroendocrine Tumors: Current Status and Review of the Literature

Pet Tracers for Somatostatin Receptor Imaging of Neuroendocrine Tumors: Current Status and Review of the Literature

Diagnosis of Zollinger–Ellison Syndrome in the Era of Ppis, Faulty Gastrin Assays, Sensitive Imaging and Limited Access to Acid Secretory Testing

68Ga-Somatostatin Analogue PET/CT in Neuroendocrine Tumors

Contact Info

Product

Resources

About